vertex journavx - Search News

FDA, Journavx

Hosted on MSN · 2h

FDA approves new pain medication as an alternative to opioids: What to know about Journavx

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under the brand name Journavx.

MassLive · 35m

FDA approves new type of non-addictive painkiller from Boston drug company

The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive risks of opioids.

FiercePharma · 15h

Vertex scores FDA nod for long-awaited non-opioid pain reliever Journavx

Vertex has gained the FDA's approval for its non-addictive pain med Journavx, which becomes the first significant innovation in pain relief in more than two decades.

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

5h

Cautious Outlook on Vertex Pharmaceuticals Amid Journavx Approval and Pricing Concerns

Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence ...

1h

Vertex Pharmaceuticals Shares Are Up Today: What's Going On?

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...

3h

What's Happening With VRTX Stock?

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

3h

Buy Rating for Vertex Pharmaceuticals: FDA Approval of Journavx Boosts Market Potential and Stock Price Target

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results